• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.

    5/14/25 10:39:48 AM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)


    Personalis, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    71535D106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    71535D106


    1Names of Reporting Persons

    ARK Investment Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,188,197.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,188,197.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,188,197.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.14 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    71535D106


    1Names of Reporting Persons

    Catherine D. Wood
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,188,197.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,188,197.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,188,197.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.14 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Personalis, Inc.
    (b)Address of issuer's principal executive offices:

    6600 Dumbarton Circle Fremont, CA, 94555
    Item 2. 
    (a)Name of person filing:

    (i) ARK Investment Management LLC ("ARK") (ii) Catherine D. Wood
    (b)Address or principal business office or, if none, residence:

    ARK and Catherine D. Wood: 200 Central Avenue, St. Petersburg, FL 33701
    (c)Citizenship:

    (i) ARK: Delaware (ii) Catherine D. Wood: United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    71535D106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    ARK and Catherine D. Wood: 7,188,197
    (b)Percent of class:

    ARK and Catherine D. Wood: 8.14%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) ARK: 7,188,197 (ii) Catherine D. Wood: 0

     (ii) Shared power to vote or to direct the vote:

    (i) ARK: 0 (ii) Catherine D. Wood: 7,188,197

     (iii) Sole power to dispose or to direct the disposition of:

    (i) ARK: 7,188,197 (ii) Catherine D. Wood: 0

     (iv) Shared power to dispose or to direct the disposition of:

    (i) ARK: 0 (ii) Catherine D. Wood: 7,188,197

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    No client of ARK Investment Management LLC currently has an interest in the securities reported herein in excess of 5 percent except ARK Genomic Revolution ETF, a series of a Delaware statutory trust.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ARK Investment Management LLC
     
    Signature:/s/ Kellen Carter
    Name/Title:Kellen Carter, Chief Compliance Officer
    Date:05/14/2025
     
    Catherine D. Wood
     
    Signature:/s/ Catherine D. Wood
    Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
    Date:05/14/2025
    Get the next $PSNL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    1/7/2022$27.00 → $23.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Personalis Inc.

      SC 13G/A - Personalis, Inc. (0001527753) (Subject)

      8/19/24 6:03:38 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Personalis Inc.

      SC 13G - Personalis, Inc. (0001527753) (Subject)

      7/26/24 12:56:21 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Personalis Inc.

      SC 13D/A - Personalis, Inc. (0001527753) (Subject)

      6/28/24 4:01:17 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection. "These studies continue to expand the clinical data for NeXT Personal into new areas, including neoadjuvant treatment in breast cancer and cervical cancer," said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. "We continue to be driven by our mission to provide physicians and thei

      5/22/25 6:00:00 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025, at The Depot Renaissance Hotel in Minneapolis, MN. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed

      5/14/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Reports First Quarter 2025 Financial Results

      Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study

      5/6/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      3/5/24 5:15:53 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    SEC Filings

    See more
    • Personalis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Personalis, Inc. (0001527753) (Filer)

      5/19/25 4:10:07 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.

      SCHEDULE 13G/A - Personalis, Inc. (0001527753) (Subject)

      5/14/25 10:39:48 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Personalis Inc.

      10-Q - Personalis, Inc. (0001527753) (Filer)

      5/6/25 4:24:12 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Personalis with a new price target

      Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

      5/15/25 8:13:23 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Canaccord Genuity initiated coverage on Personalis with a new price target

      Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

      3/17/25 8:20:27 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis upgraded by Needham with a new price target

      Needham upgraded Personalis from Hold to Buy and set a new price target of $8.00

      2/6/23 9:09:41 AM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Financials

    Live finance-specific insights

    See more
    • Personalis Reports First Quarter 2025 Financial Results

      Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study

      5/6/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis to Announce First Quarter 2025 Financial Results

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusio

      4/22/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

      Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. Recent Business Highlights Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024; delivered 3,285 total molecular tests for the full year of 2024 compared with 177 in 2023 Submitted for Medicare coverage in early

      2/27/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO AND COO Tachibana Aaron sold $6,390 worth of shares (1,291 units at $4.95), decreasing direct ownership by 0.78% to 165,099 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:53:11 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • SVP and Chief Legal Officer Moore Stephen Michael sold $8,291 worth of shares (1,675 units at $4.95), decreasing direct ownership by 3% to 64,200 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:51:51 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • CHIEF MEDICAL OFFICER AND EVP Chen Richard sold $4,504 worth of shares (910 units at $4.95), decreasing direct ownership by 0.72% to 124,957 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:50:02 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    See more
    • Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

      Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

      10/18/23 7:15:00 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Dr. Kenneth J. Widder Joins Personalis Board of Directors

      Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

      6/13/23 7:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Announces CEO Retirement and Transition

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th

      12/14/22 4:02:00 PM ET
      $PSNL
      Medical Specialities
      Health Care